Your account is not claimed yet. You can sign up with ORCID to claim your account.

Yasser Ged

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 6

Top Venues

Cancer

Nature reviews. Urology

Clinical cancer research : an official journal of the American Association for Cancer Research

Case reports in urology

Memorial Sloan Kettering Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Memorial Sloan Kettering Cancer Center Jul 31o 2017 - Jul 31o 2019

United States

Advanced Fellow :: Medicine

Publications

Yasser Ged, Alejandro Sanchez, Sujata Patil, Andrea Knezevic, Emily Stein, Stacey Petruzella, Kate Weiss, Cihan Duzgol, Joshua Chaim, Oguz Akin, Marina Mourtzakis, Michael T Paris, Jessica M Scott, Fengshen Kuo, Ritesh R Kotecha, Abraham Ari Hakimi, Chung-Han Lee, Robert J Motzer, Martin H Voss, Helena Furberg
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (23) (2022)
Yasser Ged, Mark C Markowski, Nirmish Singla, Steven P Rowe
The shifting treatment paradigm of metastatic renal cell carcinoma. Nature reviews. Urology 19 (11) (2022)
Amanda Smart, Michael Wynne, Ezra Baraban, Yasser Ged, Armine Smith
Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma. Case reports in urology 2022 (2022)
Ridwan Alam, Hiten D Patel, Zhuo T Su, Joseph G Cheaib, Yasser Ged, Nirmish Singla, Mohamad E Allaf, Phillip M Pierorazio
Self-reported quality of life as a predictor of mortality in renal cell carcinoma. Cancer (2021)
Yasser Ged, Mark C Markowski, Phillip M Pierorazio
Advanced renal cell carcinoma and COVID-19 - a personal perspective. Nature reviews. Urology 17 (8) (2020)
Darren R Feldman, Yasser Ged, Chung-Han Lee, Andrea Knezevic, Ana M Molina, Ying-Bei Chen, Joshua Chaim, Devyn T Coskey, Samuel Murray, Satish K Tickoo, Victor E Reuter, Sujata Patil, Han Xiao, Jahan Aghalar, Arlyn J Apollo, Maria I Carlo, Robert J Motzer, Martin H Voss
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer 126 (24) (2020)

Yasser Ged.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yasser Ged